Straits Times Index
3,272.72 +47.55 (+1.47%) S&P 500
5,062.50 +51.90 (+1.04%) Dow
38,452.31 +212.33 (+0.56%) Nasdaq
15,668.91 +217.60 (+1.41%) Bitcoin USD
66,815.10 +440.41 (+0.66%) CMC Crypto 200
1,438.22 +23.46 (+1.66%)
ABBV Jan 2025 240.000 call
| Previous close | 0.2600 |
| Open | 0.2600 |
| Bid | 0.2000 |
| Ask | 0.4700 |
| Strike | 240.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.2600 - 0.2600 |
| Contract range | N/A |
| Volume | |
| Open interest | 465 |
PR NewswireAllergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is offering consumers an opportunity to be featured in upcoming campaigns for their biggest brands, including BOTOX® Cosmetic, the JUVÉDERM® Collection of Fillers, and Allē, the Allergan Aesthetics loyalty rewards program. Beginning today, consumers—including existing patients and those who are considering aesthetic treatment—can apply for a chance to be included in future brand campaigns. The first Allergan Aesthetics open casting call for BO
ZacksAbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
Investor focus is likely to be on the sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports first-quarter results.
ZacksEarnings Preview: AbbVie (ABBV) Q1 Earnings Expected to Decline
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
